Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a limited portion of the infection-related content is supported by the provided label excerpts. Several safety-management, combination-risk, and clinical decision/timing statements are unsupported. The IL-17A inhibitor mechanism claim and multiple specific monitoring/administration assertions are not supported by the provided label text.
Category Scores
Accurate Statements
Cosentyx can increase the risk of infections.
Supported by 17 Patient Counseling Information (Infections): COSENTYX may lower ability of immune system; serious infections (including opportunistic) may occur.
Cosentyx safety information includes infections as an important risk.
Supported by 17 Patient Counseling Information (Infections).
Opportunistic infections are a concern with immune-modulating biologics.
Supported by 17 Patient Counseling Information (Infections): serious infections, including opportunistic infections, may occur.
Patients are generally advised to contact a clinician promptly if they develop signs of infection.
Partially supported by 17 Patient Counseling Information (Infections): instructs patients to contact doctor if they develop any symptoms of infection; provided label excerpt does not include the specific symptom list.
Clinicians may consider ensuring vaccinations ... are up to date before changing biologics.
Partially supported by 17 Patient Counseling Information (Immunization): live vaccines not recommended during COSENTYX and instructs patients to inform the healthcare practitioner prior to potential vaccination. Provided excerpt does not address infection screening or timing before changing biologics.
Unsupported Statements
Cosentyx (secukinumab) is an IL-17A inhibitor.
Not supported by the provided label excerpts/sections.
Cosentyx is used for conditions like plaque psoriasis and psoriatic arthritis.
Plaque psoriasis indication is supported by 1.1, but psoriatic arthritis is not mentioned in the provided label excerpts.
The infection risk is most relevant for infections that are already common in people with chronic inflammatory diseases.
Not supported by the provided label excerpts.
The infection risk can be higher if treatment with Cosentyx is combined with other immune-modulating therapies.
The provided infection counseling does not specifically state higher risk with combination immune-modulating therapies.
Respiratory and skin infections are among the types commonly monitored in IL-17–targeted therapies.
Not supported by the provided label excerpts.
If an infection happens during Cosentyx treatment, clinicians assess severity and may hold therapy until the infection is controlled.
Not supported by the provided label excerpts.
The infection risk can be higher in people with a history of recurrent or serious infections.
Not supported by the provided label excerpts.
The infection risk can be higher with concomitant use of other immunosuppressing medicines.
Not supported by the provided label excerpts.
The infection risk can be higher in conditions that weaken the immune system.
Not supported by the provided label excerpts.
Patients are generally advised to contact a clinician promptly if they develop signs of infection such as fever, chills, worsening cough, shortness of breath, burning or pain with urination, new or worsening skin redness/swelling, or any infection that does not improve.
The provided label excerpt instructs patients to contact the doctor for symptoms of infection but does not provide the specific symptom list.
Temporarily holding Cosentyx during an active infection is a common clinical approach, especially for more serious infections.
Not supported by the provided label excerpts.
Restarting Cosentyx depends on infection resolution and clinician judgment.
Not supported by the provided label excerpts.
Clinicians may consider switching to a different biologic class or adjusting the overall treatment regimen if infection risk is a problem.
Not supported by the provided label excerpts.
Clinicians may consider reducing or avoiding additional immunosuppressive medications if infection risk is a problem.
Not supported by the provided label excerpts.
Clinicians may consider ensuring vaccinations and infection screening are up to date before changing biologics.
The provided label excerpt supports live vaccine guidance and informing the healthcare practitioner prior to vaccination, but does not support infection screening or pre-switch timing before changing biologics.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Mechanistic characterization (IL-17A inhibition) and detailed infection risk management statements (hold/restart, regimen changes, combination-risk specifics, and patient symptom list) are not substantiated by the provided excerpts; these omissions contribute to incorrect or misleading guidance within the claimed infection-management content.
Importance:
High
Broader indications (beyond plaque psoriasis) such as psoriatic arthritis are not supported by the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or partially supported infection-management and monitoring/symptom-list claims could mislead clinical decision-making and patient actions. Only general infection risk counseling is supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple clinically actionable statements about infection risk modifiers and infection management (hold/restart, combination-therapy risk specifics, symptom checklist, switching/adjusting regimens) are unsupported by the provided label excerpts.
Suggested Improvement
Limit claims to what is supported by the provided label excerpts: infection counseling that COSENTYX may lower immune ability to fight infections and that serious infections including opportunistic infections may occur, plus immunization guidance (live vaccines not recommended during treatment and informing the HCP prior to potential vaccination). Remove or rephrase unsupported mechanism, indication scope (psoriatic arthritis), specific monitoring types, and infection-management actions.